Human VH Fragments from Transgenic Mice
Crescendo Biologics is building a pipeline of novel medicines based on its highly innovative VH antibody fragment platform.
Crescendo’s unique transgenic mouse platform rapidly and predictably generates high-affinity human heavy chain-only antibodies using the natural process of in vivo B-cell development following immunisation. VH single domain fragments from these heavy chain-only antibodies require no humanisation, making this a rapid and reliable route to candidate quality VH therapeutics.
VH fragments are the smallest portions of immunoglobulin that retain target specificity and potency and the most robust antibody fragments in terms of stability, ease of engineering and manufacture. This makes them highly attractive therapeutic agents with significant advantages in the development of products for local and topical delivery, pure antagonists and bi- or multi-specifics.